<difference-title>

De Les Feux de l'Amour - Le site Wik'Y&R du projet Y&R.
(Page créée avec « Careful inspection of these genes reveals some that may have relevance to acute lymphoblastic leukemia, and so drugs for [http://gwilymgold.com/vanilla/discussion/1400557/... »)
 
m
 
(6 révisions intermédiaires par un utilisateur sont masquées)
Ligne 1 : Ligne 1 :
Careful inspection of these genes reveals some that may have relevance to acute lymphoblastic leukemia, and so drugs for [http://gwilymgold.com/vanilla/discussion/1400557/discussion-the-epidermal-growth-factor-receptor-family-is-of-tremen-dous-biological-and-clinical-imp Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors] which these are targets provide potential can didates for repurposing. [http://www.health-style.ru/vanilla/discussion/2992/discussion-the-epidermal-growth-factor-receptor-family-is-of-tremen-dous-biological-and-clinical-imp Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors] FGFR1 is the drug target of Palifer min, a recombinant human keratinocyte growth factor for the treatment of oral mucositis associated with chemotherapy and radiation therapy. Its also the target for several experimental [http://gwilymgold.com/vanilla/discussion/1400535/discussion-the-epidermal-growth-factor-receptor-family-is-of-tremen-dous-biological-and-clinical-imp Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors] drugs. Thus, one of the high scoring ALL potential drug targets has now been approved for use for use with a new drug. Methods Connecting GWAS reported genes with drug targets using drug indication information from Drugbank GWAS reported genes The GWAS catalog was down loaded from. txt in January 2012. Non disease traits were removed by hand and multiple studies for each disease were com bined into unique sets. Reported genes were extracted to provide the list of GWAS genes for each disease. Drug targets Drugbank data were downloaded from in January 2012. Drugs for each disease in the GWAS list were identified by searching the indication information for all drugs in Drugbank. Then for each of these drugs, we extract all of the corresponding target genes. Verified drug targets Drug targets with the entry Pharmacological action labeled as Yes in the Drugbank. All 4013 GWAS reported genes and 1463 drug targets were mapped to NCBI gene IDs to provide unique identi fiers for comparison.  
+
The supportive data for this hypothesis includes the in vitro observations that these are genes induced when an EGFR [http://wittwertrainingsystems.com/forum/discussion/340284/discussion-the-epidermal-growth-factor-receptor-family-is-of-tremen-dous-biological-and-clinical-imp Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors] dependent cell line is freed from growth inhibition via EGFR inhibitors and the in vivo associations between the high expression of these signa tures and genes including HRAS, KRAS and EGFR itself. Regardless of the classical markers of activation of the [http://sm1ttysm1t.com/vanilla/discussion/561633/discussion-the-epidermal-growth-factor-receptor-family-is-of-tremen-dous-biological-and-clinical-imp Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors] EGFR RAS MEK pathway, the strong associations between these expression profiles and patient outcomes in two dif ferent data sets suggest that they are important profiles. Currently, we have chosen only to validate our profiles using additional microarray [http://gwilymgold.com/vanilla/discussion/1400582/discussion-the-epidermal-growth-factor-receptor-family-is-of-tremen-dous-biological-and-clinical-imp Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors] data sets, as opposed to using western blots or quantitative PCR of the training set, since each of these signatures represents a large number of genesproteins. A better understanding of each subtypes EGFR signaling pathway will have an impact on identifying and determining treatment as the gene expression signature may more readily be associated with activation of the pathway than EGFR status alone. Methods Cell culture SUM102 and SUM149 cells were a gift from Steve Ethier of Wayne State University and represent cell lines derived from ER and HER2 basal like breast tumors.  
  
For the 88 GWAS diseases with drugs in Drugbank, there are 1914 GWAS reported genes and 821 drug targets. The verified drug target set has 353 genes for 81 diseases. For each disease, we compare the list of GWAS reported genes and drug targets and find the overlap between these two lists. Calculating expected overlap between GWAS reported genes and drug targets using a random model We assume there are 20,000 human genes. For a specific disease, if there are m GWAS reported genes, and there are n drug targets for this disease the expected random overlap between the two gene lists for that disease is n m20000. We calculated the expected overlap for each disease and summed these to get the expected total number of overlaps between drug targets and GWAS reported genes for the same disease. SNP impact analysis for GWAS genes and drug target genes 1000 genomes VCF data were downloaded from The 2010 November data set is used. We extracted all non synonymous variants from 1000 genomes data based on Refseq annotation downloaded from the UCSC genome browser in Jan 2012, and calculated the allele frequency for each of the non reference variants by dividing the number of alleles by the number of total possible. We found non synonymous SNPs in the coding regions of 3550 out of the 4013 GWAS reported genes and 1249 out of the 1463 drug targets. The density of common non synonymous SNPs in each gene is calculated by dividing the number of non synon ymous SNPs with frequencies 5% for that gene by the length of that genes protein sequence provided by the UCSC genome browser.
+
The SUM cell lines were maintained in an Epithelial Growth Medium developed by the Tissue Culture Facility at the University of North Carolina at Chapel Hill, and the SUM149 line was further supplemented with 5% FBS. The MCF 7, ZR 75 1, HME CC and ME16C cell lines were obtained and maintained as previously described. Cytotoxicity assay Cell line sensitivities to drugs were assessed using a mito chondrial dye conversion assay as described previously with the following modifications. Cells were seeded into trip licate 96 well plates and allowed to adhere over night. Cells were treated for 72 h with a range of doses of individual drugs. Carboplatin, doxorubicin, 5 fluorour acil, paclitaxel, and LY294002 were purchased from Sigma. Gefitinib was a gift from Astra Zeneca and cetuximab was purchased from the UNC Hos pitals Pharmacy Storeroom. U0126 was purchased from Cell Signaling. The inhib itory concentration that caused a 50% reduction in MTT dye conversion dose was determined as previously described. Drug combination interactions were analyzed using methods developed by Chou and Talalay. Using cell lines plated as described above, seven treatment combina tions consisting of constant ratios of IC50 doses were applied to cells and growth compared to untreated controls using the MTT assay. Four treatment schedules were tested 72 h concurrent, 72 h inhibitor followed by 72 h chemotherapeutic, 72 h chemotherapeutic followed by 72 h inhibitor, and a 144 h concurrent dose with a media change at 72 h. CalcuSyn was used to determine the combination index, which is a measure ment of the type of drug interactions. A combination index of one indicates an additive response, less than one indicates a synergistic response, and greater than one indicates an antagonistic response. Collection of mRNA for cell line experiments For each treatment, the SUM102 cells were grown in 15 cm dishes until 5060% confluence.

Version actuelle en date du 28 décembre 2015 à 06:14

The supportive data for this hypothesis includes the in vitro observations that these are genes induced when an EGFR Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors dependent cell line is freed from growth inhibition via EGFR inhibitors and the in vivo associations between the high expression of these signa tures and genes including HRAS, KRAS and EGFR itself. Regardless of the classical markers of activation of the Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors EGFR RAS MEK pathway, the strong associations between these expression profiles and patient outcomes in two dif ferent data sets suggest that they are important profiles. Currently, we have chosen only to validate our profiles using additional microarray Discussion The epidermal growth factor receptor family is of tremen dous biological and clinical importance for many solid epithelial tumors data sets, as opposed to using western blots or quantitative PCR of the training set, since each of these signatures represents a large number of genesproteins. A better understanding of each subtypes EGFR signaling pathway will have an impact on identifying and determining treatment as the gene expression signature may more readily be associated with activation of the pathway than EGFR status alone. Methods Cell culture SUM102 and SUM149 cells were a gift from Steve Ethier of Wayne State University and represent cell lines derived from ER and HER2 basal like breast tumors.

The SUM cell lines were maintained in an Epithelial Growth Medium developed by the Tissue Culture Facility at the University of North Carolina at Chapel Hill, and the SUM149 line was further supplemented with 5% FBS. The MCF 7, ZR 75 1, HME CC and ME16C cell lines were obtained and maintained as previously described. Cytotoxicity assay Cell line sensitivities to drugs were assessed using a mito chondrial dye conversion assay as described previously with the following modifications. Cells were seeded into trip licate 96 well plates and allowed to adhere over night. Cells were treated for 72 h with a range of doses of individual drugs. Carboplatin, doxorubicin, 5 fluorour acil, paclitaxel, and LY294002 were purchased from Sigma. Gefitinib was a gift from Astra Zeneca and cetuximab was purchased from the UNC Hos pitals Pharmacy Storeroom. U0126 was purchased from Cell Signaling. The inhib itory concentration that caused a 50% reduction in MTT dye conversion dose was determined as previously described. Drug combination interactions were analyzed using methods developed by Chou and Talalay. Using cell lines plated as described above, seven treatment combina tions consisting of constant ratios of IC50 doses were applied to cells and growth compared to untreated controls using the MTT assay. Four treatment schedules were tested 72 h concurrent, 72 h inhibitor followed by 72 h chemotherapeutic, 72 h chemotherapeutic followed by 72 h inhibitor, and a 144 h concurrent dose with a media change at 72 h. CalcuSyn was used to determine the combination index, which is a measure ment of the type of drug interactions. A combination index of one indicates an additive response, less than one indicates a synergistic response, and greater than one indicates an antagonistic response. Collection of mRNA for cell line experiments For each treatment, the SUM102 cells were grown in 15 cm dishes until 5060% confluence.

Outils personnels